title: Usefulness of serum CA-15.3 in the management of benign breast lesion.
abstract: Benign breast lesion is an important risk factor for breast cancer and elevated CA-15.3 in serum is a well established marker of breast cancer. Core-needle biopsy is now the method of choice to sample non-palpable mammographic abnormality and as well as clinically palpable lesion. To asses relationship of serum CA-15.3 with different histologic entities of benign breast lesion and usefulness of this marker in predicting breast cancer in this high risk group, a study was conducted among 140 patients who had a diagnosis of benign breast lesion and malignancy following fine needle aspiration cytology (FNAC) at department of surgery, Medical College, Kolkata between 2007 and 2009. We prospectively estimated serum CA-15.3 level in all patients. Different histologic entities of benign breast lesion, who showed serum CA-15.3 level >30U/ml underwent tru-cut biopsy to detect malignancy. Of 140 patients studied, 50 were stamped as malignancy and 90 as benign after FNAC of which 20 patients had fibroadenoma, 25 had fibro-adenoma with fibrocystic disease, 20 had fibrocystic disease with epitheliosis and 25 had fibrocystic disease with atypia. All breast cancer patients and 10 each from fibro-adenoma with fibrocystic disease, fibrocystic disease with epitheliosis and fibrocystic disease with atypia had serum CA -15.3 level>30U/ml. Thirty patients with benign breast lesion who had raised CA-15.3 underwent core-needle biopsy. Fifteen patients were detected to have intraductal carcinoma, mostly with fibrocystic disease with atypia. Clinical applicability of serum CA-15.3 to detect breast cancer should be strongly considered in management of patients with benign breast lesion and tru-cut biopsy than FNAC be done before benign breast lesion being stamped as benign. Biopsy results that are not concordant with the targeted lesion require surgical biopsy.
authors.affiliation: Department of Surgery, Medical College, Kolkata 700073.
authors.forename: Hari Pada
authors.initials: HP
authors.lastname: Mondal
authors.forename: Himanshu
authors.initials: H
authors.lastname: Roy
authors.forename: Palash
authors.initials: P
authors.lastname: Mondal
authors.forename: Mita
authors.initials: M
authors.lastname: Saha
authors.forename: Nandita
authors.initials: N
authors.lastname: Basu
mesh_terms: D000293:Adolescent; D000328:Adult; D001943:Breast Neoplasms / Q000097:blood / Q000175:diagnosis*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000097:blood / Q000175:diagnosis; D005260:Female; D018226:Fibroadenoma / Q000097:blood / Q000175:diagnosis; D005348:Fibrocystic Breast Disease / Q000097:blood / Q000175:diagnosis*; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D018396:Mucin-1